Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent Malignant Gliomas
NCT00923117Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2008
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in malignant glioma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival at 6 months. Started Jun 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00923117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923117.